These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

534 related items for PubMed ID: 21771207

  • 1. The natural history of mild haemophilia: a 30-year single centre experience.
    Tagliaferri A, Di Perna C, Riccardi F, Pattacini C, Rivolta GF, Franchini M.
    Haemophilia; 2012 Mar; 18(2):166-74. PubMed ID: 21771207
    [Abstract] [Full Text] [Related]

  • 2. DDAVP responsiveness in children with mild or moderate haemophilia A correlates with age, endogenous FVIII:C level and with haemophilic genotype.
    Seary ME, Feldman D, Carcao MD.
    Haemophilia; 2012 Jan; 18(1):50-5. PubMed ID: 21592259
    [Abstract] [Full Text] [Related]

  • 3. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.
    Shirahata A, Fukutake K, Higasa S, Mimaya J, Oka T, Shima M, Takamatsu J, Taki M, Taneichi M, Yoshioka A, STUDY GROUP ON FACTORS INVOLVED IN FORMATION OF INHIBITORS TO FACTOR VIII AND IX PREPARATIONS.
    Haemophilia; 2011 Sep; 17(5):771-6. PubMed ID: 21682824
    [Abstract] [Full Text] [Related]

  • 4. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
    Björkman S, Folkesson A, Berntorp E.
    Haemophilia; 2007 Jan; 13(1):2-8. PubMed ID: 17212717
    [Abstract] [Full Text] [Related]

  • 5. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
    Croteau SE, Cheng D, Cohen AJ, Holmes CE, Malec LM, Silvey M, Thornburg CD, Wheeler AP, Kouides PA, Raffini LJ, Neufeld EJ.
    Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
    [Abstract] [Full Text] [Related]

  • 6. Risk of inhibitor development in mild haemophilia A increases with age.
    Mauser-Bunschoten EP, Den Uijl IE, Schutgens RE, Roosendaal G, Fischer K.
    Haemophilia; 2012 Mar; 18(2):263-7. PubMed ID: 21851507
    [Abstract] [Full Text] [Related]

  • 7. Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan.
    Taki M, Shirahata A.
    Haemophilia; 2009 Jan; 15(1):78-82. PubMed ID: 18700841
    [Abstract] [Full Text] [Related]

  • 8. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation.
    Hay CR, Ludlam CA, Colvin BT, Hill FG, Preston FE, Wasseem N, Bagnall R, Peake IR, Berntorp E, Mauser Bunschoten EP, Fijnvandraat K, Kasper CK, White G, Santagostino E.
    Thromb Haemost; 1998 Apr; 79(4):762-6. PubMed ID: 9569189
    [Abstract] [Full Text] [Related]

  • 9. Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients.
    Gouw SC, Van Der Bom JG, Van Den Berg HM, Zewald RA, Ploos Van Amstel JK, Mauser-Bunschoten EP.
    Haemophilia; 2011 Mar; 17(2):275-81. PubMed ID: 21070499
    [Abstract] [Full Text] [Related]

  • 10. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
    Gaboulaud V, Parquet A, Tahiri C, Claeyssens S, Potard V, Faradji A, Peynet J, Costagliola D, Suivi Thérapeutique National des Hémophiles Group.
    Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
    [Abstract] [Full Text] [Related]

  • 11. Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients.
    Epstein J, Xiong Y, Woo P, Li-McLeod J, Spotts G.
    Haemophilia; 2012 Mar; 18(2):187-92. PubMed ID: 21883704
    [Abstract] [Full Text] [Related]

  • 12. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
    Ahnström J, Berntorp E, Lindvall K, Björkman S.
    Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
    [Abstract] [Full Text] [Related]

  • 13. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
    Harper P, Brasser M, Moore L, Teague L, Pitcher L, Ockelford P.
    N Z Med J; 2003 Aug 22; 116(1180):U561. PubMed ID: 14581983
    [Abstract] [Full Text] [Related]

  • 14. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
    Biss TT, Chan AK, Blanchette VS, Iwenofu LN, McLimont M, Carcao MD, Association of Hemophilia Clinic Directors of Canada (AHCDC), Canadian Association of Nurses in Hemophilia Care (CANHC).
    Haemophilia; 2008 Sep 22; 14(5):923-30. PubMed ID: 18637844
    [Abstract] [Full Text] [Related]

  • 15. Comparing bleed frequency and factor concentrate use between haemophilia A and B patients.
    Nagel K, Walker I, Decker K, Chan AK, Pai MK.
    Haemophilia; 2011 Nov 22; 17(6):872-4. PubMed ID: 21342368
    [Abstract] [Full Text] [Related]

  • 16. Cost-of-illness study of severe haemophilia A and B in five French haemophilia treatment centres.
    Nerich V, Tissot E, Faradji A, Demesmay K, Bertrand MA, Lorenzini JL, Briquel ME, Pouzol P, Woronoff-Lemsi MC.
    Pharm World Sci; 2008 Jun 22; 30(3):287-92. PubMed ID: 18085428
    [Abstract] [Full Text] [Related]

  • 17. Severe and moderate haemophilia A and B in US females.
    Di Michele DM, Gibb C, Lefkowitz JM, Ni Q, Gerber LM, Ganguly A.
    Haemophilia; 2014 Mar 22; 20(2):e136-43. PubMed ID: 24533955
    [Abstract] [Full Text] [Related]

  • 18. The role of natural VWF/FVIII complex concentrates in contemporary haemophilia care: a guideline for the next decade.
    Mannucci PM.
    Haemophilia; 2012 May 22; 18 Suppl 2():2-7. PubMed ID: 22530573
    [Abstract] [Full Text] [Related]

  • 19. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.
    Dodd C, Watts RG.
    Haemophilia; 2012 Jul 22; 18(4):561-7. PubMed ID: 22221939
    [Abstract] [Full Text] [Related]

  • 20. F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity.
    Miller CH, Benson J, Ellingsen D, Driggers J, Payne A, Kelly FM, Soucie JM, Craig Hooper W, Hemophilia Inhibitor Research Study Investigators.
    Haemophilia; 2012 May 22; 18(3):375-82. PubMed ID: 22103590
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.